Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?

Premium

Bulk drug maker Symbiotec Pharmalab is planning to explore the possibility of floating an initial public offering in the next financial year, it is gathered. The Indore-based firm is eyeing to kickstart its public listing plans next year which will likely provide an exit to its private equity backers MOAlts and ......